Parkinson's disease
Conditions
Interventions
Low dose group:GM-1 was given intravenously, 100 mg / d
High dose group:GM-1 was given intravenously, 200 mg / d
Sponsors
Qilu Hospital of Shandong University
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Male or female subjects, aged > 30 years and <= 70 years; 2. Subjects who met the "diagnostic criteria for Parkinson's disease" formulated by the International Movement Disorders Association (MDS) in 2015; 3. Patients with early Parkinson's disease, course of disease < 10 years, Hoehn Yahr 1-3 grade; 4. The subjects who received a stable dose of dopserazide tablets, dopamine receptor agonists or monoamine oxidase type B inhibitors for one month before study enrollment; 5. Subjects who signed informed consent.
Exclusion criteria
Exclusion criteria: 1. Patients with disturbance of consciousness, aphasia and mental illness; Patients with major depression; 2. Patients with parkinsonism and secondary parkinsonism (hepatolenticular degeneration, hepatic encephalopathy, cerebellar disease, hydrocephalus, parathyroid disease, etc.); 3. Patients with long-term use of dopamine blockers (e.g. powerful nerve stabilizer, sibelium, reserpine, metoclopramide, etc.); 4. Patients who used GM1 within three months; 5. Patients with transient ischemic attack within six months; 6. Subjects with two or more stroke history or stroke sequelae within 6 months before enrollment; 7. Patients with hereditary abnormal glucose and lipid metabolism (ganglioside accumulation disease, such as familial amaurosis and retinal degeneration); 8. Patients with Guillain Barre syndrome, chronic idiopathic peripheral neuropathy and polyneuropathy; 9. Patients with positive ganglioside antibody; 10. Patients allergic to monosialotetrahexosylganglioside sodium injection; 11. Long term exposure to any known neurotoxins that may cause Parkinson's disease; Long term or short-term use of any drug that may cause dyskinesia; 12. Subjects of stereotactic brain surgery for PD; 13. Patients with severe cardiopulmonary instability, liver and kidney dysfunction (more than 3 times of normal value); 14. Patients who can't cooperate with neuropsychological test; 15. Patients who do not follow the prescribed treatment plan have poor compliance; 16. Patients considered unsuitable by the researchers.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| scores of motor symptoms and non-motor symptoms and the changes of plasma oxidative stress markers; | — |
Countries
China
Contacts
Public ContactLiu Yiming
Qilu Hospital of Shandong University
Outcome results
None listed